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Abstract
Background: Testicular germ cell tumors (TGCTs) are classified as seminonas or non-seminomas of which a major subset is
embryonal carcinoma (EC) that can differentiate into diverse tissues. The pluripotent nature of human ECs resembles that of
embryonic stem (ES) cells. Many Wnt signalling species are regulated during differentiation of TGCT-derived EC cells. This study
comprehensively investigated expression profiles of Wnt signalling components regulated during induced differentiation of EC
cells and explored the role of key components in maintaining pluripotency.
Methods: Human embryonal carcinoma cells were stably infected with a lentiviral construct carrying a canonical Wnt
responsive reporter to assess Wnt signalling activity following induced differentiation. Cells were differentiated with all-trans
retinoic acid (RA) or by targeted repression of pluripotency factor, POU5F1. A Wnt pathway real-time-PCR array was used to
evaluate changes in gene expression as cells differentiated. Highlighted Wnt pathway genes were then specifically repressed using
siRNA or stable shRNA and transfected EC cells were assessed for proliferation, differentiation status and levels of core
pluripotency genes.
Results: Canonical Wnt signalling activity was low basally in undifferentiated EC cells, but substantially increased with induced
differentiation. Wnt pathway gene expression levels were compared during induced differentiation and many components were
altered including ligands (WNT2B), receptors (FZD5, FZD6, FZD10), secreted inhibitors (SFRP4, SFRP1), and other effectors
of Wnt signalling (FRAT2, DAAM1, PITX2, Porcupine). Independent repression of FZD5, FZD7 and WNT5A using transient as
well as stable methods of RNA interference (RNAi) inhibited cell growth of pluripotent NT2/D1 human EC cells, but did not
appreciably induce differentiation or repress key pluripotency genes. Silencing of FZD7 gave the greatest growth suppression in
all human EC cell lines tested including NT2/D1, NT2/D1-R1, Tera-1 and 833K cells.
Conclusion: During induced differentiation of human EC cells, the Wnt signalling pathway is reprogrammed and canonical Wnt
signalling induced. Specific species regulating non-canonical Wnt signalling conferred growth inhibition when targeted for
repression in these EC cells. Notably, FZD7 repression significantly inhibited growth of human EC cells and is a promising
therapeutic target for TGCTs.
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Background
Embryonal carcinoma (EC) cells are the undifferentiated
and pluripotent component of germ cell nonseminoma
tumors. Some EC cell lines can be induced to differentiate
in response to cellular or pharmacological morphogens.
These cells share many features in common with embryonic stem (ES) cells and their induced differentiation
mimics critical stages of early embryogenesis [1]. Additional evidence indicating that EC and ES cells are closely
related comes from their shared gene expression profiles,
which are highly specific to germ cells and pluripotent ES
cells [2]. These species include the transcription factors
POU5F1 and Nanog, bone morphogenetic protein family
member GDF-3, developmental pluripotency-associated
gene 3 (DPPA3) and fibroblast growth factor 4 (FGF4).
The Wnt signalling pathway is essential for normal
eukaryotic development and inappropriate activation of
Wnt signalling occurs in many cancers [3]. Wnt ligands
engage signal transduction through multiple receptors
including the Frizzled transmembrane receptor family,
co-receptors LRP5 and LRP6 and receptor tyrosine
kinases, Ryk and ROR2 [4]. There are 19 Wnt ligand and
10 Frizzled receptor genes in the mammalian genome.
The canonical Wnt-Frizzled signalling pathway results in
stabilization of β-catenin allowing it to enter the nucleus
and activate transcription of Wnt target genes by binding
to T-cell factor/lymphoid enhancer factor (TCF/LEF) [5].
Frizzled receptors also play a key role in the planar cell
polarity (PCP) pathway that is responsible for orienting
cells relative to each other, and in a G protein-dependent
pathway that triggers the release of calcium (Ca2+) [5]. The
other Wnt receptors Ryk and Ror2 can signal through Src
and JNK intermediates, respectively [6]. Wnt signalling
proteins promote expansion of stem cells in diverse tissue
contexts including the mammary gland, hematopoietic
system, and the brain, underscoring the importance of
this signalling pathway in stem cell maintenance [7].
The multipotent EC cell line NT2/D1 differentiates along
a neuronal lineage in response to all-trans retinoic acid
(RA) treatment, which is associated with loss of both selfrenewal capacity and expression of pluripotent specific
genes [8]. NT2/D1 cells were derived from a metastasis of
a human testicular germ cell tumor (TGCT) and these
retain the pathognomonic cytogenetic marker and cellular
features of this malignancy [1,9]. In our initial studies to
identify key species regulating early differentiation steps,
several components of the Wnt signalling pathway were
affected by RA-treatment [8]. This study sought to build
on that prior work by comprehensively examining the
expression and activity of Wnt species during induced differentiation of NT2/D1 cells and in a well characterized
panel of TGCT cell lines including a derived RA-resistant
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cell line, NT2/D1-R1 [10]. Given that this pathway is
important for both the maintenance of pluripotency and
in regulating specific differentiation steps, it was hypothesized that during induced differentiation, the Wnt signalling machinery was reprogrammed in EC from a pathway
supporting pluripotency to one promoting differentiation. Findings reported here provide substantial evidence
confirming this hypothesis and these implicate the therapeutic potential of targeting the Wnt pathway in human
EC and other TGCTs.

Methods
Cell Culture and Clonal Growth Assays
NT2/D1, NT2/D1-R1, Tera-1, 833K and 293T human cells
were cultured in high glucose DMEM (InVitrogen, CA)
containing 100 U/ml penicillin, 100 μg/ml streptomycin,
2 mM glutamine, and 10% fetal bovine serum (FBS) at
37°C under humidified 5% CO2. RA was dissolved in
dimethyl sulfoxide (DMSO) as a 10 mM stock solution
and stored in liquid nitrogen. Cells were treated with RA
(10 μM), which was refreshed every 48 hours, while control cells were treated with DMSO vehicle alone. For colony formation assays, NT2/D1 and NT2/D1-R1 were
independently plated at 5000 and 2500 cells per well,
respectively, in six well tissue culture plates in triplicate.
After 10-14 days, colonies were stained using Diff Quick
(Imeb, Inc., CA) and quantified using the ColCount
instrument (Oxford Optitronix, UK). Replicate experiments were performed to confirm results.
siRNA Silencing
Double-stranded small interfering RNAs (siRNAs) with
19-nucleotide duplex RNA and a 2-nucleotide deoxythymidine overhang at the 3' region were synthesized (Dharmacon, CO and Qiagen, CA). Two different siRNAs were
designed to target independently human POU5F1, FZD5
and FZD7 mRNAs. The sequences chosen were: FZD5-1
5'-ATCACGGTGCCCATGTGCC-3', FZD5-2 5'-TCCTAAGGTTGGCGTTGTA-3',
FZD7-1
5'-AACGGCCTGATGTACTTTA-3', FZD7-2-2 5'-GGCCAGCTTGTGCCTAATA3', POU5F1-2 5'-AGCAGCTTGGGCTCGAGAA-3' and
POU5F1-3 5'-GAAAGAACTCGAGCAATTT-3'. Control
siRNAs used were firefly luciferase pGL2 siRNA (5'CGTACGCGGAATACTTCGA-3') and RISC free (5'GCGCGCTTTGTAGGATTCG-3'), the latter is not a substrate for the RNAi silencing complex (RISC) (Dharmacon, CO). Transfection of siRNAs was accomplished
with OligofectAMINE (Invitrogen, CA), as previously
described [11]. To assess effects on cell growth, EC cells
were trypsinized 24 hours after transfection and plated at
5 × 104 cells per well in 6-well plates. Triplicate wells were
counted for each time point post-transfection and each
experiment was performed at least three independent
times. Results were expressed as mean ± standard devia-
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tion for a representative experiment. Subsequent assays
for growth of small hairpin RNA (shRNA)-transduced
cells were plated in the same way, but cell growth measurements were performed using the Cell Titre-Glo Assay
(Promega, WI), which uses ATP content as an indicator of
cell number.
Immunoblot Analysis
Cells were lyzed in a modified radioimmune precipitation
buffer, as described [12]. Protein concentrations were
determined using the BCA protein assay kit (Thermo Scientific, IL). Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to
nitrocellulose membranes. Antibodies used and dilutions
were FZD5, 1:500 (06-756 Upstate, NY), FZD7, 1:250
(AF198 R&D Systems, MN), active-β-catenin (ABC) 1:500
(05-665, Upstate, NY), β-catenin 1:2000 (MD, 610153,
BD Transduction Laboratories), JNK and phospho-JNK
1:1000 (9258 and 9251, Cell Signaling Technology, Inc.
MA), Oct3/4/POU5F1, 1:750 (H-134, Santa Cruz, CA), αtubulin 1:1000 (CP06, Calbiochem, CA) and actin 1:2000
(C11, Santa Cruz, CA). Membranes were blocked in trisbuffered saline with 0.1% Tween 20 (TBS/Tween) plus 5%
non-fat milk powder and primary antibodies were also
diluted in 5% milk powder in TBS/Tween except for the
ABC antibody which was diluted in 1% milk powder as
previously described [13] and the JNK antibodies that
were in 5% bovine serum albumin. Primary antibodies
were detected with horseradish peroxidase conjugated
secondary antibodies (Santa Cruz, CA and Amersham, IL)
and visualized using the enhanced chemiluminescence
system (Amersham, IL). For FZD5 and FZD7 detection,
cellular lysates were not frozen and run under non-reducing conditions (without β-mercaptoethanol or boiling).
Lentivirus Production and Luciferase Assays
The Topflash lentiviral vector was obtained from Dr. Karl
Willert (University of California, San Diego). Silencing
shRNA constructs were purchased (Open Biosystems, AL).
To generate lentiviral particles, the desired plasmid and
lentiviral packaging plasmids pCMV-dR8.2 dvpr and
pCMV-VSVG (Addgene.com) were transfected into 293T
cells using FuGENE 6 (Roche, Germany). Medium was
changed 18 hours after transfection and viral particles
were harvested twice over the next 72 hours. Cells were
infected with the lentiviral supernatant for 24 hours in the
presence of 4 μg/ml of polybrene (Sigma-Aldrich, MO).
After 48 hours, cells were replated in 10-cm dishes. For
shRNA lentiviral constructs, infected cells were selected by
addition of 0.5 μg/ml puromycin (Sigma-Aldrich, MO).
The Topflash lentiviral vector does not carry an antibiotic
selectable marker and pools of cells were maintained for
subsequent analyses. Luciferase activity was measured
using the Promega (WI) luciferase assay system and normalized to protein concentrations, as above.
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Analysis of Wnt Signalling Pathway Genes
To assess regulated expression of Wnt pathway members
following RA-mediated differentiation of NT2/D1 cells,
real-time quantitative reverse transcription-polymerase
chain reaction (RT-PCR) assays were performed. The RT2
Profiler™ PCR Array PAHS-043 (SABiosciences, MD) was
used for these analyses. Total cellular RNA was isolated
using TriReagent (Molecular Research Center, OH) and
cDNA was synthesized from 1 μg of total RNA according
to the manufacturer's instructions (SABioscience). Thermal cycling was performed using an Applied Biosystems
7500 Fast Real Time PCR System and real-time amplification data were obtained using ABI 7500 Fast System SDS
software. Gene expression was normalized to internal
controls (housekeeping genes) to determine fold changes
in gene expression between test and control samples
(SABioscience, MD). For the profiler arrays, the SYBR
green PCR mix used was from -SABiosciences (MD). For
real-time RT-PCR analyses of individual gene products,
cDNA synthesis and SYBR green PCR reagents were purchased from Applied Biosystems (CA). Primer sequences
used for real-time RT-PCR assays appear in additional
file 1.
Differentiation Marker Studies
Indirect fluorescence-activated cell sorter (FACS) analyses
to evaluate RA-induced neuronal differentiation of NT2/
D1 cells were performed using previously established
methods [14]. Briefly, NT2/D1 cells were harvested by
trypsinization and incubated with monoclonal antibodies
to established human EC differentiation markers. The
A2B5 antibody was isolated from a hybridoma culture
and recognizes a neuronal epitope in RA-treated NT2/D1
cells (ATCC, VA). SSEA-3 (Developmental Studies Hybridoma Bank, University of Iowa, U.S.A.) recognizes an
embryonal antigen, which is lost as EC cells differentiate
[15]. Cells were indirectly assayed with Alexa 488 nM conjugated goat anti-mouse or goat anti-rat antibodies (Invitrogen, CA) and fluorescence was measured, as described
[14].
Statistics
Where a value for statistical significance is indicated a two
sample two-tailed t-test assuming unequal sample variances was performed.

Results
Induction of canonical Wnt signalling during human EC
differentiation
Stable integration of a canonical Wnt response element
into NT2/D1 human EC cell pools allowed kinetic measurement of canonical Wnt activity. Transient transfection
of a Wnt responsive reporter had been inconclusive in
NT2/D1 cells induced to differentiate (data not shown).
Similar studies examining the expression of the human
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cyclin D1 promoter in these cells also required stable integration of the promoter to recapitulate the expression pattern of the endogenous gene [16]. The chromatin of
pluripotent cells is viewed as distinct from that of differentiated cells. It was reported that certain chromatin proteins in ES cells are hyperdynamic, binding loosely to
chromatin [17]. This "breathing" chromatin both characterized pluripotent cells and was functionally relevant to
their ability to differentiate into multiple cell types.

ern analysis is shown in Figure 1b. POU5F1 levels were
efficiently repressed by the siRNA and the repression of
POU5F1 protein levels following 3 days of RA treatment
is also shown. Under continued RA treatment, luciferase
levels remained high, however beyond 9 days of POU5F1
siRNA treatment, luciferase levels fell as POU5F1 protein
levels returned to normal (data not shown).

Little Wnt reporter luciferase activity was detected in basal
cultures, but when RA was added, the levels of Wntresponsive luciferase activity increased markedly over
vehicle treated-matched control cells (Figures 1a, 1d).
When these NT2/D1 cells were induced to differentiate by
repression of the key pluripotency transcription factor
POU5F1, the level of canonical Wnt signalling increased
within 3 days and was over 6-fold elevated after 7 days
(Figure 1a). Validation of POU5F1 knockdown by west-

a

c

b

d
POU5F1

RA

vehicle

POU5F1-3

RISC

Actin

Relative Luciferase
Activity

Protein lysates from treated cells were analysed using the
activated β-catenin (ABC) antibody, which specifically
recognizes the nonphosphorylated form of β-catenin
[18]. The ABC epitope is revealed during canonical Wnt
signalling and pharmacological inhibition of glycogen
synthase kinase 3 (GSK3) by lithium chloride. The levels
of ABC were clearly elevated following 6 days of RA treatment relative to vehicle treated cells (Figure 1c), and with
24 hours of lithium chloride treatment. The levels of total
β-catenin were also elevated by these treatments, which
reflects the stabilization of the hypophosphorylated form

200
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Figure 1 Wnt signalling is induced with human EC differentiation
Canonical
Canonical Wnt signalling is induced with human EC differentiation. NT2/D1 cells carrying a stably integrated multimerized canonical TCF-transcription factor binding site luciferase reporter were induced to differentiate. Luciferase activity
was measured to determine the level of activity in the canonical Wnt signalling pathway and expressed relative to protein concentration. a) NT2/D1 cells transfected with siRNA for the transcription factor POU5F1 or control siRNA, and RA or vehicle
control for 3, 7 and 9 days. b) Western validation of POU5F1 knockdown 3 days post siRNA transfection. POU5F1 levels of
cells treated with RA were also measured after 3 days. c) Active-β-catenin levels in NT2/D1 cells following RA treatment. Lithium chloride (20 mM 24 hours) was used as a control to show activation of β-catenin, sodium chloride controlled for salt concentration. d) Time course of RA treatment over 7 days measuring integrated canonical Wnt reporter activity. Error bars
represent standard deviation.
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of β-catenin. The ABC levels were also elevated following
knockdown of POU5F1, although to a lesser extent than
with RA treatment, between 3 and 7 days post transfection
(data not shown). Therefore, canonical Wnt signalling, as
measured by Wnt reporter activity, is minimal in basally
growing EC cells and activated as these cells are induced
to differentiate.
Multiple Wnt pathway genes are regulated during induced
EC differentiation
To build on prior work, analyses of Wnt pathway gene
expression were performed in NT2/D1 cells induced to
differentiate and results were compared to controls. Differentiation was conferred with 4 days of RA (10 μM)
treatment or with siRNA transfection to repress the
pluripotency associated transcription factor POU5F1. RA
treatment caused significant regulation of 6 of 16 Wnt ligands and 4 of 8 Frizzled receptors (Figure 2). Of the 84
genes analysed, 33 were significantly regulated following
4 days of RA treatment (Additional file 2). The analyses

a

following siRNAs targeting POU5F1 revealed 11 of 84
species were significantly regulated, 10 of which were
shared with the RA-regulated species (Additional file 3).
The levels of Wnt ligands in RA-treated and control cells
are presented in Figure 2a. Of the 16 ligands examined,
the most abundantly expressed in untreated cells was
WNT5A. The cycle at which fluorescence exceeded a
defined threshold (CT score) in this analysis varied widely
for Wnt ligands with most being barely detected (i.e. CT
score greater than 30). With RA-treatments, the levels of
WNT2B increased markedly to levels above that of
WNT5A. This is in agreement with our earlier studies
using degenerate PCR primers for Wnt ligand analysis. In
untreated cells, all the PCR products sequenced corresponded to WNT5A and after RA treatment the majority of
PCR products sequenced were WNT2B with some WNT5A
transcripts detected (data not shown). The prominent
Wnt mRNAs expressed in this system are WNT5A and
WNT2B. WNT3, WNT4, WNT6, and WNT10A were significantly up-regulated after 96 hours of RA-treatment and
WNT5B and WNT9A were significantly down-regulated
by this treatment (Figure 2a).
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*

* *
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0.4

*

0.3
0.2
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FZD8

FZD7

FZD6

FZD5

FZD4

FZD3

FZD2

0
FZD1

Relative Gene Expression

b

Figure
Gene
human
expression
EC
2 cells of Wnt ligands and Frizzled receptors in
Gene expression of Wnt ligands and Frizzled receptors in human EC cells. Real-time RT-PCR arrays were
used to determine the gene expression profiles of Wnt ligands and Fzd receptors in NT2/D1 cells relative to housekeeping genes. Graphs represent averages and standard
deviations of at least 3 independent RNA samples. Graphs
depict the gene expression profiles of a) Wnt ligands and b)
Fzd receptors in NT2/D1 cells treated +/- RA for 4 days. (* p
< 0.05, **p < 0.005).

The expression of the Frizzled receptors varied less than
for the Wnt ligands with moderate expression evident for
each one (i.e., no CT score greater than 30). FZD1, FZD3
and FZD6 were each significantly up-regulated following
RA-treatment and FZD5 was significantly down-regulated.
FZD7 mRNA levels were the highest (i.e., it had the lowest
CT score), but this was not as marked as for the differences
detected in levels of the Wnt ligands.
The species most substantially up-regulated in response to
both of these differentiation signals were WNT2B, SFRP4
and PITX2. In each case, these species were up-regulated
over 100-fold after RA-treatment and 10- to 30-fold for
cells transfected with POU5F1 siRNAs. WNT2B up-regulation had been observed during both RA- and hexamethylene bisacetamide (HMBA)-mediated differentiation of EC
cells, confirming these changes are not confined to RAtreatment, but associated with induced differentiation
[19]. PITX2 is a transcription factor associated with leftright asymmetry and is up-regulated by both RA and
canonical Wnt signalling pathways [20-23]. SFRP4 is one
of the secreted frizzled-related protein family members
thought to compete with membrane bound frizzled
receptors for Wnt binding [24].
It was hypothesised that loss of the POU5F1 transcription
factor in EC cells would result in repression of POU5F1
target genes and this was found for the known POU5F1target gene, FGF4, which was repressed about 3-fold
(Additional file 3). In RA-treated EC cells, FGF4 expres-
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sion was repressed over 500-fold, suggesting mechanisms
in addition to loss of POU5F1 act to reduce its mRNA levels. In these analyses PORCN, FRAT2, and FZD5 were each
repressed following POU5F1 targeted repression, but this
did not achieve statistical significance. Using independent
primers for these species, each was verified as significantly
repressed by both RA-treatment and POU5F1 repression
in EC cells, implying these are potential POU5F1 target
genes (Figure 3a and additional file 4).
siRNA-mediated repression of FZD5 or FZD7 in EC cells
In searching for therapeutic targets of the Wnt signalling
pathway, the G-protein coupled receptor (GPCR)-like
Frizzled 5 (FZD5) and Frizzled 7 (FZD7) were chosen for
further analyses. FZD5 was chosen because it is repressed
as EC cells are induced to differentiate; FZD7 was selected
since it was prominently expressed in EC and ES cells [2].

Western analyses of NT2/D1 cell lysates two days after
transfection, showed repression of FZD5 and FZD7 with
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FZD5 Expression
(% Control)
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400
300
200
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0
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Tera 1

WNT5A Expression
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siRNA sequences targeting each receptor (Figure 4a). Figure 4a is a representative immunoblot result and the cells
lyzed for this were not from the same experiment as those
used for the cell growth assay in Figure 4b. With siRNA
FZD5-1 there is a clear repression of FZD5 protein while
FZD5-2 has a reduced repression of FZD5 relative to the
RISC and untreated cells. The levels of FZD5 protein were
repressed in lysates from FZD7 siRNA transfected cells relative to the controls. This observation was made consistently with the two independent siRNA sequences
targeting FZD7 and is viewed to be a consequence of
FZD7 repression. The FZD7 protein levels were clearly
repressed by the FZD7-2 siRNA, but not by the FZD7-1
siRNA or any of the other conditions. In a previous experiment harvested 3 days following siRNA transfection, this
result was reversed and repression of FZD7 was only
apparent with the FZD7-1 siRNA. This may be caused by
a difference in the stability or effectiveness of the individual siRNA species or possibly a difference in the rate at
which they silence their gene targets.
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Figure 3 of FZD5, FZD7, WNT5A, and POU5F1 in human germ cell tumor cell lines
Expression
Expression of FZD5, FZD7, WNT5A, and POU5F1 in human germ cell tumor cell lines. Real-time RT-PCR assays
were used to independently determine the expression of a) FZD5, b) FZD7, c) WNT5A, and d) POU5F1 in NT2/D1, NT2/D1R1, Tera-1, and 833K cells. Gene expression profiles were determined in cells treated with +/- RA for 4 days. Values are
expressed as percent of NT2/D1 (-RA), which served as a control. Graphs depict representative PCR assays performed in triplicate. Error bars represent standard deviation.
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using established immunophenotypic markers recognized by A2B5 and SSEA-3, as in prior work [14]. These
experiments did not reveal a substantial loss of the
pluripotency-associated antigen SSEA-3 or gain of the
neuronal specific antigen A2B5 (data not shown). Since
the duration of siRNA-mediated repression might not be
sufficient for the 6-day study time course, stable repression of FZD5 and FZD7 was sought using lentiviral shRNA
infection of targeted cells.

b

Number of NT2/D1
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Figure of
Knockdown
growth
4 ECofcells
FZD5 and FZD7 leads to a reduction in
Knockdown of FZD5 and FZD7 leads to a reduction
in growth of EC cells. NT2/D1 and NT2/D1-R1 cells were
individually transfected with siRNAs to knockdown FZD5 or
FZD7, or with a control siRNA construct, pGL2 or RISC.
Graphs depict a representative experiment performed in
triplicate. Error bars represent standard deviation. a) Expression of FZD5 and FZD7 proteins in NT2/D1 cells was quantified using immunoblotting on non-reducing gels. b) Number
of NT2/D1 cells and c) number of NT2/D1-R1 cells after 4
days compared to initial number of seeded cells. (* p < 0.05,
**p < 0.005, ***p < 0.0005).

The day following siRNA transfection, cells were replated
at equal densities and counted 24 and 96 hours later to
determine growth effects. Both FZD5 and FZD7 repression resulted in significantly reduced cell numbers, with
repression of FZD7 consistently achieving greater growth
suppression than FZD5 in both NT2/D1 and its RA-resistant clone NT2/D1-R1 (Figure 4b and 4c). Experiments
were performed to determine if siRNA mediated repression of FZD5 or FZD7 in EC cells induced differentiation,

One arm of the non-canonical Wnt signalling pathway
activates JNK. To determine if either FZD5 or FZD7 were
acting through JNK, the levels of activated-JNK in protein
lystaes were examined from cells treated with siRNAs to
FZD5 and FZD7. No significant changes in phospho-JNK
levels were detected 3 days following siRNA transfection
in any sample (additional file 5). In human synovial sarcoma cells this was sufficient time to see repression of JNK
activation following siRNA-mediated repression of
FZD10 [25]. Future studies aim to extend the time course
examined following receptor repression and to overexpress the receptors to see if JNK activation increases.
Stable repression of FZD5 and FZD7 in human EC cells
Five separate lentiviral targeting constructs were individually tested for effective silencing of FZD5 and FZD7 (Figure 5a and 5b). Substantial repression of FZD5 mRNA was
confirmed for all five constructs with most efficient
repression detected with constructs FZD5-2, FZD5-4, and
FZD5-5 (Figure 5a). Only 3 of the 5 FZD7 constructs
appreciably repressed FZD7 mRNA and these were FZD72, FZD7-3 and FZD7-4. For FZD5, the constructs resulting
in the most efficient repression of FZD5 mRNA levels also
produced a significant inhibition of EC cell colony formation (Figure 5c). For FZD7, the 3 constructs showing efficient knockdown of FZD7 mRNA also showed significant
repression of colony formation (Figure 5c). Construct
FZD7-3 achieved the greatest growth inhibitory effect, but
also exhibited off-target effects since it did not confer the
highest repression of FZD7 expression and also caused
moderate reduction of FZD5 mRNA. Cell growth experiments assessing cell number over 4 days confirmed the
colony formation assay findings (data not shown).

To determine if stable repression of FZD5 or FZD7 in EC
cells induced differentiation, expression of immunophenotypic differentiation-specific extracellular markers recognized by A2B5 and SSEA-3 were each examined. Cells
were selected on puromycin for at least 14 days before this
drug was removed for 48 hours and cells were harvested
for analyses. As with the siRNA-mediated repression of
these receptors described above, there were no consistent
changes in differentiation marker expression (data not
shown). Expression patterns of several pluripotency-associated factors were examined including POU5F1, Nanog
and FGF4. These species were not regulated by FZD5 and
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infected with lentiviral shRNAs for FZD5, FZD7, or a control
shRNA. Graphs depict a representative experiment performed in triplicate. a) FZD5 and b) FZD7 expression profiles were determined using real-time RT-PCRs. Results
presented are an average of duplicate readings. c) The ability
of the cells to form colonies when plated at a low density is
shown. Error bars represent standard deviation. (* p < 0.05,
**p < 0.005).

FZD7 repression (Figure 6b and data not shown). Thus,
repression of FZD5 and FZD7 expression in human NT2/
D1 EC cells inhibited growth, but did not impact expression of several key pluripotency factors.
Inhibition of WNT5A expression in EC cells
WNT5A was the most highly expressed Wnt ligand uncovered in basally growing NT2/D1 cells. The shRNA lentiviral vectors to silence WNT5A expression were transduced
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Knockdown of FZD7 reduces colony formation, but
does not cause loss of POU5F1 expression in EC cells.
NT2/D1-R1, 833K, and Tera-1 cells were each infected with
lentiviral shRNAs to knockdown FZD7 expression. Graphs
depict a representative experiment performed in triplicate,
displayed as percent of control for each cell line. Error bars
represent standard deviation. Real-time PCR assays were
used to determine a) FZD7 gene expression and b) POU5F1
gene expression. c) Colony formation ability of FZD7 shRNA
infected cells versus controls is displayed.

to determine if loss of this ligand impacted EC cellular
growth or differentiation. Efficient repression of WNT5A
was achieved with three different lentiviral constructs and
NT2/D1 colony formation was inhibited (additional file
6). The degree of knockdown of WNT5A mRNA did not
correlate with colony formation inhibition. Construct
WNT5A-5 had the most efficient knockdown while conPage 8 of 13
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struct WNT5A-2 caused the greatest inhibition of colony
formation. Ideally the protein levels of WNT5A would
have been examined to confirm which shRNA construct
gave the most efficient knockdown at the protein level. It
is also possible that the WNT5A-2 construct caused offtarget effects, which led to growth inhibition beyond that
seen for WNT5A alone. Repression of WNT5A in NT2/D1
cells did not repress expression of pluripotency-associated
factors POU5F1, FGF4 or Nanog (data not shown).
Inhibition of FZD7 inhibits human EC cell growth
To ensure that the growth inhibitory effects seen in NT2/
D1 cells were not cell line specific, other human EC and
germ cell tumor cell lines were infected with the lentiviral
constructs targeting FZD5 and FZD7. Transduced cells
were examined for changes in cell growth and pluripotency-associated gene expression. The cell lines used were
NT2/D1-R1 an RA resistant clone of NT2/D1 cells [10],
Tera-1 and 833K cells, which were derived from lung and
abdominal testicular cancer metastases, respectively
[26,27]. Expression levels of FZD5, FZD7, WNT5A and
POU5F1 were first examined to confirm each line was
expressing similar levels of these species (Figure 3). Cells
were analyzed +/- RA-treatment (10 μM) and, as expected,
only NT2/D1 cells appreciably responded to RA-treatment
by repressing FZD5 and POU5F1 expression. NT2/D1-R1
cells were selected for RA resistance and Tera-1 and 833K
cells were studied since they were known not to differentiate with RA-treatment [28]. Untreated NT2/D1, NT2/
D1-R1 and Tera-1 cells expressed similar amounts of
FZD5 mRNA relative to the GAPDH expression levels and
833K cells expressed 2-4-fold higher levels. Tera-1 cells
had approximately 10-fold lower and 833K and NT2/D1R1 cells had 2-fold lower levels of FZD7 mRNA expression
levels relative to NT2/D1 cells. WNT5A mRNA levels were
also about 10-fold lower in Tera-1 and 833K cells and 5fold lower in NT2/D1-R1 than in NT2/D1 cells. POU5F1
mRNA levels were similar in all four untreated cell lines
examined.

In colony formation and proliferation assays, FZD5
repression conferred using lentiviral vectors FZD5-2 and
FZD5-4 did not produce consistent growth inhibitory
effects in NT2/D1-R1, Tera-1 or 833K cells (data not
shown). However, repression of FZD7 using constructs
FZD7-2 and FZD7-4 consistently caused substantial
growth inhibition in all the cells tested. A representative
experiment is displayed (Figure 6). Expression levels of
FZD7 measured by real-time-RT-PCR assays were reduced
to between 15-30% of control levels in NT2/D1-R1, Tera1 and 833K cells (Figure 6a). This was sufficient to inhibit
cell growth, but did not impact expression of the pluripotency-associated gene POU5F1, Nanog or FGF4 (Figure 6b
and data not shown). Therefore, while Frizzled receptor
FZD7 is playing an important role in EC cell growth, it is
not impacting key pluripotency factors in these cells.
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Discussion
Canonical Wnt signalling is associated with proliferation
and is deregulated in cancer [3]. Wnt target genes include
cyclin D1 and c-myc, both of which are also associated
with proliferation and are over-expressed in several cancers [3]. Human NT2/D1 EC cells have high levels of cyclin D1 and c-myc, which are both repressed as these cells
are induced to differentiate [16,29]. Based on this, it was
hypothesised that canonical Wnt signalling would be
active in the proliferative and pluripotent EC cells and
repressed in these cells induced to differentiate with a concurrent loss of tumorigenicity. In fact, the opposite was
observed with canonical Wnt signalling at low levels in
basally growing cells and elevated levels as cells were
induced to differentiate, exemplifying the paradoxical
nature of Wnt signalling in ES and EC cells. This is also
reflected in prior work where some studies report that
canonical Wnt signalling supports ES cell self-renewal and
pluripotency and others have found that canonical Wnt
signalling can induce ES cell differentiation, as reviewed
[30]. Different cell lines and methodologies were used in
these reports and might account for the apparent discrepant results. Also, the level of nuclear β-catenin and the origin of ES cells might determine how these cells respond to
canonical Wnt signalling activation.
The EC cells examined here respond in a similar way to
murine embryos in which Wnt signalling is not evident
until day 6.5 when reporter activity is seen at the posterior
of the embryo where the primitive streak begins to form
[31]. Embryoid bodies generated from Wnt reporter carrying ES cells also showed polarized Wnt activation, and the
Wnt responsive cells were enriched for mesoendodermal
gene expression [31,32]. Using a similar functional
reporter assay in ES cells, it was found that transcriptional
activity of the canonical Wnt pathway is minimal until the
cells are induced to differentiate [33]. In immunohistochemical studies of pediatric TGCTs, the EC specimens
examined had low-levels of nuclear β-catenin while teratomas, which are the differentiated counterpart of these
tumors, had elevated levels of nuclear β-catenin [34,35].
In combination with the observations reported here, this
confirms the similarities in Wnt signalling between EC
and ES cells.
From these analyses, several Wnt receptors and ligands
were abundantly expressed in undifferentiated EC cells
and repression of several of these species inhibited EC cell
growth. WNT5A was the most abundant Wnt mRNA of
the 16 examined in this study and this ligand has been
most commonly associated with non-canonical Wnt signalling [36]. It is likely that non-canonical Wnt pathways
are functioning in human EC cells to maintain their cell
division. The distinct chromatin structure of EC and ES
cells may be responsible for the lack of β-catenin-mediated transcription and it has been proposed that one role
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of POU5F1 is to block canonical Wnt signalling [17]. It
was hypothesised that inhibition of WNT5A, the dominant Wnt ligand in the NT2/D1 system, would result in a
more marked phenotype than repression of single frizzled
receptors. As this was not the case, this indicates that
either other Wnt ligands are playing redundant roles in
this system and/or that the frizzled receptors are functioning without ligand, as reviewed [4]. Additionally, while
WNT5A mRNA levels were higher than that of other Wnt
ligands, as assessed by real-time RT-PCR assays, it is not
known if this relates to appreciably higher levels of Wnt
protein or activity.
Many of the changes in Wnt gene expression seen in
induced differentiation of EC cells are also seen in
induced differentiation of ES cells, highlighting the use of
the EC system as a model for Wnt signalling in ES cell
biology. Other studies looking at POU5F1 target genes in
human and mouse ES cells proposed that PORCN, FRAT2,
and FZD5 were potential POU5F1 target genes [37,38]. In
a bioinformatics study, POU5F1 transcription factor binding sites were conserved among mammalian FZD5
orthologs [39]. Both SFRP1 and SFRP2 are downregulated
in response to RA-treatment of EC cells [8,40] and in
response to POU5F1 repression in murine ES cells [37].
Of equal interest are the species strongly induced with
both methods of differentiation, which include SFRP4,
PITX2 and WNT2B. The induction of these species may be
due to changes in chromatin resulting from the loss of
POU5F1 activity or other mechanisms.
The dichotomous roles Wnt signalling plays in proliferation versus differentiation are especially evident in studies
of neurogenesis. Differences in model systems and techniques may partially explain some of the discrepancies.
However, it seems increasingly likely that the complexity
of Wnt pathway allows for distinct signaling outputs
within a cell. Recently, coactivator usage by β-catenin has
been shown to determine proliferative versus differentiation gene transcription programs [41-43] and manipulation of specific coactivator levels could maintain
pluripotency in murine ES and EC cells [42]. In addition
to the increase in activated β-catenin seen as NT2/D1 cells
are induced to differentiate, coactivator usage by β-catenin
may also be changing and we aim to investigate this in
future studies.
To target the Wnt signalling pathway, it was decided to
specifically repress the expression of the FZD5 and FZD7
receptors. FZD5 was down-regulated in response to differentiation of NT2/D1 cells and in human melanoma cells
FZD5 activation by WNT5A had been associated with elevated metastatic potential [44]. FZD5 repression was
growth suppressive in NT2/D1 cells, but was not as effective in the other TGCT cell lines tested. FZD7 was high-
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lighted in a study to identify species preferentially
expressed in ES and EC cells [2] and was significantly
growth suppressive in all the EC cell lines studied here.
FZD7 has also been identified as a potential therapeutic
target in hepatocellular and colorectal cancers [45,46].
Targeted repression of FZD7 was growth suppressive for
all EC cells tested, but this did not cause differentiation of
these cells. This is in contrast to a recent paper where
shRNA-mediated repression of FZD7 decreased POU5F1
expression substantially in human ES cells and moderately in the human EC cell line NCCIT [47]. These differences may be due to the distinct features of the cell lines
used. Also, human ES cells may respond differently than
human EC cells. A single shRNA construct was used in the
human ES cell study, which caused a 60-fold knockdown
of FZD7 mRNA, whereas the greatest knockdown
achieved with our panel of shRNA constructs was 20-fold
repression. In agreement between these reports were the
observed phenotypic cell changes. For the human ES cells,
this was particularly evident at the edges of colonies,
whereas the NT2/D1 cells became elongated and spindlelike with repressed FZD7 expression (data not shown).
Many of the non-canonical Wnt signalling pathways target the cytoskeleton, as in melanoma where non-canonical signalling by WNT5a is found to correlate with
metastatic potential and invasiveness [44]. Recently, it
was reported that WNT5a polarizes the cytoskeleton,
allowing chemokine directed motility in melanoma cell
lines [48]. TGCTs are highly metastatic and may be utilizing this pathway to enter the blood system and then
spread to other sites. Subsequent studies aim to examine
the role of Wnt pathways in EC cell motility and differentiation-induced cytoskeletal changes. Initial focus will be
on DAAM1 and profilin-1, two proteins involved in actin
organization and non-canonical Wnt signalling and upregulated as EC cells are induced to differentiate along a
neuronal lineage (Additional file 2 and [49]).
The complexity of the Wnt signalling pathway is due to in
part to the large number of potential ligands and receptors. In addition, challenges exist in developing pharmacological tools to specifically inhibit Wnt ligand activity
that have made this pathway difficult to dissect. Wnt ligands were historically divided into those resulting in
either canonical or non-canonical signalling. With the discovery of more Wnt receptors, non-Wnt ligands and Wntindependent Frizzled activation, a new view of the Wnt
pathway is being proposed: that it is the receptor and
downstream effector context, in addition to ligand identity, which determines ultimate signalling output [4]. The
established role of Wnt signalling in development and its
misregulation in cancer and other diseases highlights the
need for a more complete understanding of how this
pathway works. Novel pharmacological tools to inhibit
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Wnt signalling are becoming available [50]. This will
accelerate the evaluation of the therapeutic possibilities of
Wnt pathway manipulation in human EC and other
tumors.

Conclusion
EC cells are the malignant counterparts of ES cells, with
induced differentiation of EC cells mimicking many stages
of early embryogenesis. Multiple components of the Wnt
pathway are regulated as EC cells are induced to differentiate; many of these are also regulated in differentiating
human ES cells. The human EC cell system is therefore an
attractive model to explore Wnt signalling before confirming observations in the more practically complex ES cell
context. Despite minimal canonical Wnt activity in
basally growing EC cells, specific repression of Wnt receptor FZD7 resulted in consistent growth inhibition of
human EC cells, implicating non-canonical Wnt pathways
in maintaining EC cell proliferation. FZD7 is preferentially expressed in EC cells and is therefore an attractive
therapeutic target for human ECs.
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Additional file 3
Gene expression changes in NT2/D1 cells treated with siRNA to
POU5F1. Raw Wnt array data from NT2/D1 cells treated with siRNA to
POU5F1 or a control siRNA for 96 hours.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712407-9-383-S3.xls]

Additional file 4
Effect of differentiation on PORCN, FRAT2, and FZD5 expression.
NT2/D1 cells were treated with RA or transfected with siRNA for
POU5F1 to induce differentiation. A real-time PCR assay was used to
determine expression of PORCN, FRAT2, and FZD5, respectively.
Expression is displayed as percent of control. Graphs depict an average of
at least two RNA samples with real-time RT-PCR assays performed in triplicate. Error bars represent standard deviation. a) PORCN expression. b)
FRAT2 expression. c) FZD5 expression. (**p < 0.005, ***p < 0.0005).
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712407-9-383-S4.pdf]

Additional file 5
Knock-down of FZD5 and FZD7 expression with siRNA does not
impact the levels of activated JNK. NT2/D1 cells were transfected with
siRNA and cell lysates harvested after 72 hours. Lysates were blotted with
antibodies specific for the activated form of JNK (phospho-JNK), total
JNK and β-actin.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712407-9-383-S5.tiff]

Additional file 6
Knock-down of WNT5A leads to a reduction in colony formation.
NT2/D1 cells were infected with lentiviral shRNAs to knockdown
WNT5A expression, and results were compared to a control shRNA.
Graphs depict a representative experiment performed in triplicate. Error
bars represent standard deviation. a) WNT5A expression was measured
using a real-time PCR assay. b) The ability of the cells to form colonies
when plated at a low density is displayed. (* p < 0.05).
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712407-9-383-S6.pdf]
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